Literature DB >> 23474970

Altered mental status in cirrhosis: etiologies and outcomes.

Robert S Rahimi1, Alan C Elliott, Don C Rockey.   

Abstract

BACKGROUND: Cirrhotic patients admitted with altered mental status (AMS) represent a clinical challenge, as many potentially life-threatening diseases must be considered. Although many patients with AMS have hepatic encephalopathy (HE), other causes of AMS occur, and we hypothesized that these may have different outcomes. AIM: We aimed to understand the causes of AMS in cirrhotic patients admitted to the hospital and investigate their associated outcomes.
METHODS: We performed a retrospective cohort study in 1218 inpatients with cirrhosis. Altered mental status was defined a priori (HE, sepsis/infectious, metabolic, exogenous drugs/toxins, structural lesions, or psychiatric abnormalities).
RESULTS: Patients with AMS had higher levels of serum bilirubin, international normalized ratio, blood urea nitrogen, creatinine, and lower levels of albumin and platelets than those with normal mental status (NMS) (P = < 0.001). The most common cause of AMS was HE, accounting for nearly half of all patients. Other causes of AMS included the following: sepsis/infection (23%), metabolic disorders (8%), drugs/toxins (7%), structural lesions (5%), psychiatric disorders (1%), or multiple causes (8%). Mortality in patients with AMS was 35% compared to 16% in those with NMS (P < 0.0001). Patients with sepsis/infection, structural lesions, or multiple disorders causing AMS had the highest mortality (61%, 68%, and 79%, respectively).
CONCLUSIONS: Nearly one third of admissions in cirrhotic patients were due to AMS, most commonly caused by HE. The overall mortality of patients admitted with AMS was greater than with NMS, particularly for those with infection or structural lesions, emphasizing the importance of a search for these causes of AMS in all patients with cirrhosis.

Entities:  

Mesh:

Year:  2013        PMID: 23474970     DOI: 10.2310/JIM.0b013e318289e254

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  7 in total

1.  Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations.

Authors:  Xinmei Wang; Bo Yu; Wei Ren; Xiaokui Mo; Chenguang Zhou; Hongyan He; Huliang Jia; Lu Wang; Samson T Jacob; Robert J Lee; Kalpana Ghoshal; L James Lee
Journal:  J Control Release       Date:  2013-10-08       Impact factor: 9.776

2.  Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy.

Authors:  Meghan NeSmith; Joseph Ahn; Steven L Flamm
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-02

Review 3.  Current state of knowledge of hepatic encephalopathy (part IV): Management of Hepatic Encephalopathy by liver support systems.

Authors:  Tarek Hassanein
Journal:  Metab Brain Dis       Date:  2016-12-24       Impact factor: 3.584

Review 4.  Encephalopathy in Cirrhosis: Prevention and Management.

Authors:  Amrish Sahney; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2021-12-22

5.  Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.

Authors:  Robert S Rahimi; Amit G Singal; Jennifer A Cuthbert; Don C Rockey
Journal:  JAMA Intern Med       Date:  2014-11       Impact factor: 21.873

Review 6.  Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature.

Authors:  Ricardo Badillo; Don C Rockey
Journal:  Medicine (Baltimore)       Date:  2014-05       Impact factor: 1.889

7.  Peak urea level, leukocyte count and use of invasive ventilation as risk factors of mortality in acute pancreatitis: A retrospective study.

Authors:  Chao-Nan Liu; Si Chen; Hao Chen; Li Yue; Li-Qin Ling; Chang-Wei Chen; Lei Du; Jing Zhou
Journal:  PLoS One       Date:  2019-05-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.